Does Insulin Resistance Ruin Pregnancy Outcomes in PCOS?

Polycystic ovary syndrome (PCOS) presents significant metabolic and reproductive challenges for women of childbearing age. Specifically, prepregnancy insulin resistance plays a major role in driving these difficulties. Consequently, researchers have recently examined how baseline metabolic health affects fertility treatments. Therefore, understanding this connection helps clinicians optimize preconception care.

The PPCOS II Secondary Analysis

This study utilized data from the multicenter Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial. Specifically, the team analyzed 746 women aged 18 to 40 years. All participants underwent ovulation induction using clomiphene citrate or letrozole. Furthermore, researchers measured baseline insulin resistance using the homeostatic model assessment (HOMA-IR) and other markers. They wanted to determine if baseline insulin sensitivity predicts final pregnancy outcomes.

Prepregnancy Insulin Resistance and Fertility Decline

The results demonstrated a clear link between baseline metabolic health and ovulation success. Specifically, women in the highest HOMA-IR quartiles had significantly lower ovulation rates than those in the lowest quartile. Similarly, higher prepregnancy insulin resistance was associated with a steep decline in clinical pregnancy rates. Clinical pregnancy rates dropped from 52.2% in the lowest quartile to just 31% in the highest quartile. Consequently, live birth rates also decreased significantly among women with severe insulin resistance. Therefore, high prepregnancy insulin resistance acts as a major barrier to successful conception.

Obstetric Complications and GDM Risks

Beyond immediate fertility, metabolic dysfunction poses serious risks during pregnancy. Specifically, patients in the highest HOMA-IR quartiles faced a much higher risk of gestational diabetes mellitus (GDM). The GDM rate rose to over 21% in the highest quartile compared to about 5% in the lowest. However, the study found no significant association between baseline insulin resistance and preeclampsia or preterm delivery. Additionally, changes in insulin resistance during ovulation induction did not alter the rates of ovulation, pregnancy, or GDM. Consequently, early metabolic screening remains a vital tool for clinicians.

Clinical Takeaways for Gynecologists

Preconception care for women with PCOS should prioritize metabolic optimization. Consequently, clinicians must address these abnormalities before initiating ovulation induction. For example, lifestyle modifications and insulin-sensitizing therapies may help improve metabolic parameters. Moreover, managing insulin resistance early can lower the risk of developing gestational diabetes. Ultimately, proactive metabolic management is essential for improving both reproductive and obstetric outcomes in patients with PCOS.

Frequently Asked Questions

Q1: How does prepregnancy insulin resistance affect ovulation in women with PCOS?

Research indicates that higher baseline insulin resistance significantly reduces ovulation rates during fertility treatments. Specifically, women with elevated HOMA-IR scores experience delayed ovulation and lower overall success than those with normal sensitivity.

Q2: Does prepregnancy insulin resistance increase the risk of gestational diabetes?

Yes, higher prepregnancy insulin resistance is strongly linked to an increased risk of gestational diabetes mellitus (GDM). Specifically, GDM rates were over four times higher in patients in the highest quartile than those in the lowest.

Q3: Can improving insulin resistance during fertility treatment improve pregnancy outcomes?

According to this analysis, treatment-phase changes in insulin resistance did not associate with pregnancy or live birth rates. Therefore, clinicians should focus on optimizing metabolic health before beginning ovulation induction.

References

1. Yun BH et al. Prepregnancy Insulin Resistance and Fertility and Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome. Obstet Gynecol. 2026 May 22. doi: 10.1097/AOG.0000000000006318. PMID: 42166772.
2. Legro RS et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014 Jul 10;371(2):119-29. doi: 10.1056/NEJMoa1313517.